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ABSTRACT
Our identification of dysregulation of the AKT pathway in ovarian cancer as a 
platinum resistance specific event led to a comprehensive analysis of in vitro, in 
vivo and clinical behaviour of the AKT inhibitor GSK2141795. Proteomic biomarker 
signatures correlating with effects of GSK2141795 were developed using in vitro 
and in vivo models, well characterised for related molecular, phenotypic and imaging 
endpoints. Signatures were validated in temporally paired biopsies from patients 
treated with GSK2141795 in a clinical study. GSK2141795 caused growth-arrest 
as single agent in vitro, enhanced cisplatin-induced apoptosis in vitro and reduced 
tumour volume in combination with platinum in vivo. GSK2141795 treatment in vitro 
and in vivo resulted in ~50-90% decrease in phospho-PRAS40 and 20-80% decrease 
in fluoro-deoxyglucose (FDG) uptake. Proteomic analysis of GSK2141795 in vitro and 
in vivo identified a signature of pathway inhibition including changes in AKT and p38 
phosphorylation and total Bim, IGF1R, AR and YB1 levels. In patient biopsies, prior to 
treatment with GSK2141795 in a phase 1 clinical trial, this signature was predictive of 
post-treatment changes in the response marker CA125. Development of this signature 
represents an opportunity to demonstrate the clinical importance of AKT inhibition 
for re-sensitisation of platinum resistant ovarian cancer to platinum.
INTRODUCTION
Epithelial ovarian cancer (EOC) is the most lethal 
form of gynaecological malignancy, yet it typically 
presents as a chemo-sensitive disease. This paradox 
is explained by the frequent emergence of resistance 
to current therapeutic regimens combining platinum 
compounds and taxanes [1]. Addition of further cytotoxic 
combinations have not produced clinical improvement 
[2], and thus the focus has turned to targeted therapeutics, 
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selected on the basis of our understanding of ovarian 
tumour biology.
EOC is a heterogeneous group of diseases 
representing distinct histological subtypes including 
serous, endometrioid, clear cell, and mucinous. Serous 
ovarian cancer has been further divided into Type I and 
Type II tumours which represent distinct clinical and 
genetic entities [3]. One of the most frequently activated 
pathways in EOC is the PI3K/AKT oncogenic network. 
PI3K (~40%), KRAS (~20%) and PTEN (~5%) mutations 
underlie activation in Type I tumours, whereas Type II 
tumours exhibit frequent copy number changes and over-
expression of PI3K/AKT pathway components (~46%) 
[4]. We showed that activation of AKT in platinum-
resistant cells occurs by phosphorylation of AKT at 
serine 473 by DNA-dependent protein kinase (DNA-
PK) [5] following DNA damage, directly linking the 
established role of AKT in chemo-resistance to platinum-
mediated DNA damage [4, 6, 7]. We also demonstrated 
that inhibition of AKT or DNA-PK restores sensitivity 
to platinum in clinically resistant EOC cells [5]. These 
data suggest AKT is a strong anti-cancer target for 
platinum resistant disease and several AKT inhibitors 
have been developed and are reviewed elsewhere [6, 7]. 
GlaxoSmithKline has developed GSK2141795, which is 
a potent N-alkyl pyrazole pan-AKT inhibitor, with high 
affinity for all three AKT isoforms [8, 9].
The development of drugs for treatment of cancer 
remains a slow, expensive and high-risk process with 
many compounds failing due to lack of therapeutic 
activity, toxicity and poor pharmacokinetics. Additionally, 
the difficulty in translating behaviour of anti-cancer agents 
from in vitro to in vivo, and subsequently the clinical 
environment has contributed to this failure. A key area of 
focus in the drug discovery process is identification and 
validation of reliable predictive and pharmacodynamic 
(PD) biomarkers. PD biomarkers may include cellular, 
molecular, histopathological and/or imaging parameters 
[10, 11]. Such PD biomarkers should clearly enable 
efficient and scientifically-driven “Go/NoGo” decisions 
allowing acceleration of the drug development process.
This study was designed to evaluate the activity 
of the specific AKT inhibitor GSK2141795 [9] alone 
and in combination with platinum in platinum-resistant 
ovarian cancer and to guide the clinical development of 
AKT inhibition by identifying protein-based and imaging-
based predictive and pharmacodynamic biomarkers. 
Significantly, we report the identification of a proteomic 
signature of response to AKT inhibition using in vitro 
and in vivo samples and subsequent validation using 
clinical biopsies taken before and after treatment with 
GSK2141795. This signature will be of use for predicting 
response to AKT inhibition in the clinic.
RESULTS
Inhibition of AKT results in growth arrest alone 
and apoptosis in combination with cisplatin in 
platinum-resistant ovarian cancer cells
Platinum-resistant SKOV3 cells, grown as 
monolayers, were treated with GSK2141795 alone or 
with cisplatin for 24, 48 and 72 hours. Caspase 3/7 activity 
was assessed as a marker of apoptosis at each time point. 
GSK2141795 treatment alone did not induce caspase 
activation, however significantly enhanced apoptosis 
induced by cisplatin at all time points tested (Figure 
1A and Supplementary Figure S1). Similar results were 
obtained for platinum-resistant PEO4 ovarian cancer cell 
monolayers (Figure 1B) and SKOV3 spheroids (Figure 
1C).
Cell viability in 2D-monolayers was measured 
by MTT assay, which measures cellular metabolism 
as a surrogate of viability, under conditions identical to 
apoptosis experiments. SKOV3 cells treated GSK2141795 
showed a dose dependent decrease in cell viability 
(Figure 2A). Interestingly, this was despite no increase 
in apoptosis detected by caspase 3/7 assay (Figure 1A), 
and is thus consistent with MTT changes predominantly 
representing growth arrest rather than apoptosis. 
Treatment with cisplatin alone reduced cell viability, 
and this was further decreased in a GSK2141795 dose-
dependent manner on combination (Figure 2A: >50% 
reduction with cisplatin and 5µM GSK2141795 relative 
to cisplatin-treatment alone (p < 0.01)), and the half-
maximal effective concentration of GSK2141795 in the 
combination treatment was 3μM. Cell cycle analysis by 
flow cytometry indicated G1 and G2 arrest in SKOV3 
cells treated with GSK2141795 alone, but no increase in 
apoptosis, consistent with caspase 3/7 and MTT assay data 
(Figure 2B). Co-treatment with GSK2141795 and cisplatin 
increased sub-G0/G1 fraction compared to either drug 
treatment alone, consistent with caspase activation data 
(Figure 2B and Supplementary Figure S2). 
The combinatorial effect of varying concentrations 
of cisplatin and GSK2141795 in vitro was assessed by 
isobologram analysis and indicated synergy in both 
SKOV3 and PEO4 cells (Supplementary Figure S3). 
Tumour growth rates of SKOV3 tumour-bearing 
mice were assessed following daily dosing with vehicle 
or GSK2141795 either alone or in combination with 
cisplatin. Treatment with cisplatin alone caused a 
significant decrease in tumour size compared to vehicle-
treated animals at day 14 (p < 0.05; Figure 2C). When 
GSK2141795 and cisplatin were used in combination, the 
tumour growth rates were further decreased compared to 
cisplatin only treated animals (p < 0.01; Figure 2C).
Concentrations of GSK2141795 in tumour and 
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blood taken from in vivo SKOV3 xenograft time-course 
studies were determined. GSK2141795 accumulated in 
the SKOV3 xenograft tumours during the first 24 hours 
of treatment, with 12.5 hour half-life of the drug in the 
tumour (Supplementary Figure S4). In comparison, 
GSK2141795 was elevated in the blood for 60 minutes 
following oral dosing, decreasing rapidly to low levels for 
the remainder of the time-course (Supplementary Figure 
S4). 
AKT inhibition via GSK2141795 decreases 
phosphorylation of the pharmacodynamic 
biomarker PRAS40 at Thr246 in a dose-
dependent manner
To confirm the ability of GSK2141795 to 
inhibit AKT signalling in SKOV3 cells, lysates from 
2D monolayers and 3D spheroids were treated with 
GSK2141795 and analysed for phosphorylation of 
its downstream substrate PRAS40. Treatment with 
GSK2141795 resulted in a concentration-dependent 
reduction in the ratio of phosphorylated PRAS40 (Thr246) 
Figure 1: Caspase 3/7 activity in SKOV3 and PEO4 cells exposed to GSK2141795 as a single agent or in combination 
with cisplatin. SKOV3 and PEO4 monolayers (A. and B., respectively) and SKOV3 spheroids C. were pre-treated with a range of 
concentrations of GSK2141795, 1 hour prior to treatment with cisplatin (cddp; 25 μM). Induction of caspase 3/7 activity was assessed at 24 
hours following the initiation of the treatment for the monolayers A. and B. and at 72 hours for the spheroid C.. Data shown are the means 
± SEM of 3-4 experiments performed in triplicate. *p < 0.05, **p < 0.01, ***p < 0.001 (paired t-test).
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to total PRAS40 in both SKOV3 monolayers and 3D 
spheroids (Figure 3A). Phosphorylation of PRAS40 at 
Thr246 was reduced to < 1% pretreatment level in SKOV3 
monolayers treated with GSK2141795 (5µM) for both 72 
hours (Figure 3A) and 48 hours (Supplementary Figure 
S5). Reduction in phosphorylation was only partial (~50% 
of the pretreatment level) in the 3D model at the highest 
concentration, perhaps reflecting partial penetration 
of the compound into the 3D spheroids (Figure 3A). 
Additionally, levels of phosphorylated PRAS40 were 
significantly reduced in SKOV3 xenografts following 
treatment with either GSK2141795 as a single agent (p 
< 0.01) or in combination with cisplatin (p < 0.05; Figure 
3B). This effect was not observed when using cisplatin as 
a single agent in these xenografts.
Figure 2: Effect of GSK2141795 either alone or in combination with cisplatin on the viability, cell cycle and tumor 
growth of SKOV3 cells. SKOV3 cells were exposed to a range of GSK2141795 concentrations (0.075 - 10 µM) either as a single agent 
or in combination with cisplatin (cddp; 25 µM) for 72 hours, when cell viability was measured using MTT A. Cell cycle analysis of SKOV3 
cells following treatment with GSK2141795 as a single agent (5 µM) or in combination with cisplatin (25 µM) for 24 hours B. SKOV3 
tumour-bearing mice were dosed daily with GSK2141795 (30 mg/Kg; oral) or vehicle ± biweekly cisplatin (1.5 mg/Kg; intraperitonal) for 
14 days C.. Data shown in A. and B. are the means ± SEM of 3-4 experiments performed in triplicate, and in C. the mean ± SEM for n = 8 
tumours/treatment, *p < 0.05, **p < 0.01, ***p < 0.001 (paired t-test), where the symbols *, # and + represent significant differences when 
compared to vehicle, cisplatin and GSK2141795 data at 14 days, respectively. 
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AKT inhibition by GSK2141795 decreases [3H]
FDG uptake in 2D, 3D spheroids and tumour 
xenograft models of ovarian cancer
Uptake of radiolabelled FDG into SKOV3 
monolayers and spheroids, treated with GSK2141795 
for 24 and 48 hours respectively, was measured over a 
24-hour time-course. [3H]FDG uptake into vehicle 
treated monolayers and spheroids reached a plateau at 
approximately 6 and 10 hours, respectively (t½ = 0.52 
hours (monolayers) and 3.04 hours (spheroids); Figures 
4A and 4B). Additionally, these in vitro time-course 
studies demonstrated dose-dependent decrease in FDG 
uptake upon treatment with GSK2141795 (t½ = 0.41 and 
0.53 hours for 1 and 5 µM, respectively (monolayers); 
and 5.79 and 4.30 hours for 1 and 5 µM, respectively 
(spheroids)) (Figures 4A and 4B). In addition, SKOV3 
tumour bearing mice were treated with GSK2141795 
for 1 to 72 hours prior to [18F]FDG administration. 
Uptake of [18F]FDG into SKOV3 tumours decreased in 
a time-dependent manner (t½ = 12 hours) following oral 
administration of GSK2141795 (30mg/kg; Supplementary 
Figure S4A); which results in blood and tumour Cmax 
>5µM GSK2141795 (Supplementary Figure S4B-D). 
Although maximal uptake of [3H]FDG into SKOV3 
monolayers and spheroids occurred at approximately 6 
and 10 hours respectively, it is not feasible to use these 
time points when scanning patients with [18F]FDG in 
the clinic. Therefore, dose-response studies utilising 
GSK2141795 were repeated in SKOV3 monolayers at 2 
hours (optimum time for clinical scanning; Figure 4C) and 
spheroids at both 2 and 6 hours (6 hours = optimum time 
for incubation of the tumours with radio-ligand; Figure 
4C) to allow comparison. A dose-dependent decrease in 
[3H]FDG uptake was observed in the SKOV3 monolayers 
(ED50 = 0.22 µM; Figure 4C) which formed a plateau at 
~1 µM GSK2141795. A greater concentration-dependent 
effect of GSK2141795 was observed in the SKOV3 
spheroids at both the 2 and 6 hour time-points, again 
reaching a plateau at ~1 μM, yielding similar ED50 values 
(ED50 = 0.42 µM (2 hours) and 0.18 µM (6 hours); Figure 
4C). In vivo analysis of the effect of GSK2141795 on [18F]
FDG uptake into SKOV3 xenografts indicated reduced 
[18F]FDG signal compared to vehicle reaching a maximum 
of 68% at the highest dose of 30 mg/kg of GSK2141795 (p 
< 0.05) used in this study (Figure 4D).
The relationship between decreases in FDG uptake 
in cells and changes in downstream markers of AKT 
pathway inhibition (phospho-PRAS40/total PRAS40) 
induced by GSK2141795 were evaluated in SKOV3 
monolayers and spheroids. These comparisons revealed 
a strong positive correlation between the two parameters 
over the range of GSK2141795 concentrations in both the 
SKOV3 monolayers (R2 = 0.910; Figure 4E) and spheroids 
(R2 = 0.979; Figure 4F). 
Identification of a proteomic signature of AKT 
pathway inhibition by GSK2141795 by reverse 
phase protein array
A proteomic signature of AKT pathway inhibition 
by GSK2141795 was identified through RPPA analysis 
Figure 3: Inhibition of PRAS40 phosphorylation 
by GSK2141795 in SKOV3 monolayers, spheroids 
and xenografts. Protein concentration of phospho-PRAS40 
(Thr246) and total PRAS40 was determined by enzyme-linked 
immunosorbent assay (ELISA) after 72hr treatment of SKOV3 
cells with a range of concentrations of GSK2141795 (0.01 - 5 
µM) in both monolayers and spheroids A.. GSK2141795 (30 
mg/Kg) abolished phosphorylation of PRAS40 at Thr246, 
both as single agent and in combination with cisplatin (cddp), 
in SKOV3 tumour xenografts following 14 days of treatment 
B.. Data are presented as a phospho-PRAS40 / total PRAS40 
decrease relative to untreated or vehicle treated samples. 
Data shown in A. are the means ± SEM of n = 2 experiments 
performed in triplicate, and in B. the mean ± SEM for n = 5 
animals (tumours) / treatment. *p < 0.05 and **p < 0.01, where 
the symbols * and # represent significant differences when 
compared to vehicle and cisplatin data, respectively (unpaired 
t-test, two tailed). 
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Figure 4: Effect of GSK2141795 on FDG uptake in SKOV3 monolayer, spheroids and mouse xenografts. Time-course 
of [3H]FDG uptake in SKOV3 monolayers (N = 3) A. and spheroids (N = 3, experiments performed in triplicate ± SEM) B. pre-incubated 
with either vehicle or GSK2141795 (1 and 5 µM) for 48 hours; Dose-dependent effect of GSK2141795 on the uptake of [3H]FDG into 
SKOV3 monolayers following 2 hours incubation with [3H]FDG; SKOV3 spheroids following 2 and 6 hours incubation with [3H]FDG (N 
= 3, experiments performed in triplicate ± SEM) C.; and uptake of [18F]FDG into tumours of SKOV3 xenografted mice following 5 hours 
drug treatment (10 - 30 mg/Kg; n = 3 per dose except for 20 mg/Kg where n = 1), *p < 0.05 compared to vehicle treated animals (unpaired 
t-test) D.. Pearson correlation between expression levels of phospho-PRAS40 (Thr246) and [3H]FDG uptake into SKOV3 monolayers 
E. and spheroids F. following treatment with GSK2141795. SKOV3 monolayers and spheroids were treated with varying concentrations 
of GSK2141795 for 48 hours. Phospho-PRAS40 (Thr246) and [3H]FDG uptake were analysed as described in the methods section. 
Abbreviations: DPM = decays per minute; SUV = standardised uptake values; AUC = area under the curve.
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of SKOV3 tumours grown in vivo, SKOV3 monolayers 
in vitro and PEO4 monolayers in vitro. Consistent effects 
of treatment with GSK2141795 across the range of 
environments studied (each compared to a DMSO control) 
were identified using a Rank Product meta-analysis. This 
analysis enabled assessment of the statistical significance 
of treatment effect on protein expression across the set of 
studies, and the resulting signature is given in Table 1. 
 From this proteomic signature, a subset of pathway 
alterations showing a similar change upon GSK2141795 
treatment in at least 4 of 5 experimental groups (studies) 
was identified (given in Supplementary Table S2). These 
alterations reflect the most consistent of the changes 
across all experimental models. They included an increase 
in phosphorylation of AKT at T308 and S473, increased 
phosphorylation of p38 MAPK and increases in total AR, 
Bim, IGF1R and YB1. Decreases in phosphorylation of 
S6, Rb, ACC1, 4EBP1 and PRAS40 were observed as well 
as decreases in total NF2 and Tuberin.
Table 1: Proteomic signature of protein level changes following GSK2141795 treatment 
across xenografts and cell lines as described in Materials and Methods. 
Proteins increased on GSK2141795 treatment FoldChange P-value Adj P-value
Akt_pS473 1.327855 0.000100 0.003125
Akt_pT308 2.181444 0.000100 0.003125
p38_pT180_Y182 1.144112 0.000100 0.003125
STAT5_alpha 1.304476 0.000100 0.003125
Bim 1.248445 0.001990 0.049760
IGF_1R_beta 1.144254 0.004482 0.093367
YAP_pS127 1.148339 0.006125 0.109371
GSK3_alpha_beta_pS21_S9 0.421782 0.008931 0.139550
MAPK_pT202_Y204 0.968154 0.014187 0.197044
AR 1.081206 0.017242 0.215530
YB_1 1.177568 0.031214 0.354700
    
Proteins decreased on GSK2141795 treatment FoldChange P-value Adj P-value
Cyclin_B1 0.672057 0.000100 0.003950
S6_pS235_S236 0.137526 0.000100 0.003950
S6_pS240_S244 0.194702 0.000100 0.003950
Caspase_7_cleaved_D198 0.797813 0.000126 0.003950
Rb_pS807_S811 0.709457 0.000175 0.004380
EGFR 0.799100 0.000595 0.012400
53BP1 0.875146 0.001762 0.031471
IGFBP2 0.896407 0.002767 0.043238
NF2 0.821243 0.005116 0.071056
4E.BP1_pS65 0.713764 0.010503 0.131290
Tuberin 0.788187 0.011787 0.132717
ACC1 0.864443 0.012741 0.132717
EGFR_pY992 0.961440 0.021906 0.210638
VEGFR2 0.897841 0.029226 0.248513
Fibronectin 0.807220 0.030147 0.248513
PRAS40_pT246 0.668444 0.031810 0.248513
ACC_pS79 0.858526 0.035321 0.259712
A cut-off of p<0.05 in the RankProd meta-analysis was applied.
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Proteomics-based pharmacodynamic biomarkers 
in clinical administration of drug
From each of 10 patients participating in a Phase 
I clinical trial for GSK2141795, cell lysates from one 
biopsy taken prior to treatment and one biopsy taken 
following 4 weeks (W4) of treatment with the drug were 
profiled using Reverse Phase Proteomic Arrays (as for 
the in vitro and xenograft studies) [8]. Protein levels 
in paired biopsies (pre-dose and W4 post-dose) were 
evaluated by RPPA for evidence of target inhibition 
by GSK2141795, and to obtain insight into how signal 
transduction networks responded and adapted to AKT 
inhibition. Hierarchical clustering analysis was carried 
out on RPPA data from pre and post treatment biopsies 
using a cutoff of 30% maximal decrease in CA125 as 
a definition of clinical activity (CAS: clinical activity 
signal. CAS+ >30% CA125 decrease. CAS- < 30% 
CA125 decrease). Clustering heatmaps indicate profound 
changes in signaling behaviour following GSK2141795 
treatment in the patient group with clinical activity (>30% 
CA125 decrease) (Figure 5A). Conversely in the patient 
group without clinical activity, very little effect is seen in 
the RPPA data beyond alterations in phospho-AKT itself, 
indicating drug activity but no downstream molecular 
effect (Figure 5A). As shown in Figure 5B, both total 
AKT (decreased; p = 0.02) and the phospho-AKT/total 
Figure 5: A. Hierarchical clustering heatmap of protein expression detected in RPPA from pre-treatment and W4 on-treatment biopsies. 
CAS+: patient group with clinical activity signal, and CAS-: patient group with no clinical activity signal are indicated. t0: pre-treatment and 
t4: W4 on-treatment biopsy samples. The expression level for each protein from each patient at a given time point in the CAS or non-CAS 
population is averaged and displayed in the heatmap, with data for each protein median centered. Red indicates an increase in expression and 
green represents a decrease in expression with respect to the median. Examples of significant proteins identified in the analysis are indicated 
individually. B. Comparison of the average levels of total AKT and the ratio of phospho-AKT/total-AKT between pre-treatment biopsies 
(n = 12) and the biopsies taken following 4 weeks of treatment with GSK2141795 (n = 10) for all patients. Total AKT decrease student’s 
t-test p = 0.02; phospho-AKT/total-AKT increase student’s t-test p = 0.006 C. Correlation between clinical response to administration 
of GSK2141795 and pharmacologically-induced change in protein expression profile for AKT-inhibition signature. Percentage decrease 
in patients’ CA125 levels is plotted against the difference in AKT-inhibition proteomic signature z-scores between pre-treatment biopsy 
and the biopsy taken following 4 weeks of treatment with GSK2141795 (n = 10 pairs) for the up- and down-regulated protein signatures 
(Table 1). T distribution of Pearson correlation coefficient gives p = 0.082 for up-regulated protein signature. D. Comparison of treatment-
induced decrease in CA125 (as a percentage of pre-treatment level) following 4 weeks of treatment with GSK2141795 in patients with low 
versus high pre-treatment levels of the up- and down-regulated AKT-inhibition proteomic signatures (Table 1). T distribution of Pearson 
correlation coefficient between CA125 decrease and up-regulated proteomic signature score gives p = 0.041. CAS: clinical activity signal. 
CAS+ >30% CA125 decrease. CAS- < 30% CA125 decrease.
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AKT ratio (increased; p = 0.006) showed significant fold-
changes in expression levels at W4 compared to baseline 
by RPPA in all patients regardless of CA125 response, 
consistent with pharmacodynamic target engagement, 
thus providing clinical validity of the RPPA analysis. The 
change in phospho-AKT levels at W4 correlated with 
changes seen previously by immuno-histochemistry [8].
Pharmacologically-induced changes in proteomic 
signature of AKT inhibition correlate with 
therapeutic response
Using the experimentally-derived proteomic 
signature of AKT inhibition via treatment with 
GSK2141795 (Table 1), we calculated signature scores 
to reflect the degree of AKT pathway modulation in 
this series of biopsies taken from patients undergoing 
treatment with GSK2141795 in the clinic. Clinical 
response in patients receiving the drug was inferred from 
the percentage drop in levels of the ovarian cancer marker 
CA125. Interestingly, the difference in signature scores 
between pre-treatment and post-treatment biopsies for 
each patient were correlated to the corresponding decrease 
in CA125 levels, as shown in Figure 5C. It can be seen 
that as expression levels of the in vitro GSK2141795-
upregulated proteins (see Table 1) systematically increase 
following clinical administration of the drug, there is a 
trend towards the patient’s CA125 levels decreasing 
correspondingly (p = 0.082). A similar effect is observed 
for a decrease in expression of the in vitro GSK2141795-
downregulated proteins (p = ns). This indicates that 
successful pharmacological modulation of the AKT 
pathway in ovarian tumours is reflected by a decrease in 
the patient’s overall tumour burden.
Pre-treatment expression levels of AKT-inhibition 
signature proteins are predictive of clinical 
response
The clinical activity in patients receiving 
GSK2141795, as indicated by the percentage decrease in 
CA125 levels, was significantly greater in patients with 
low pre-treatment levels of the in vitro GSK2141795-
upregulated proteins (see Table 1) than it was for the 
patients with high pre-treatment levels of these proteins. 
Figure 5D (left panel) shows the distributions of CA125 
decrease for the low-expressing group (consisting 
of patients for which z-scores for the GSK2141795-
upregulated signature were less than zero in pre-treatment 
biopsies, meaning the tumours were expressing the 
proteins at relatively low levels), and the high-expressing 
group (the remaining patients, which all had z-scores 
greater than zero). The correlation between low pre-
treatment expression of the GSK2141795-upregulated 
proteins and the treatment-induced reduction in CA125 
was statistically significant (p = 0.041), despite the small 
number of patients with paired biopsies (n = 10). A 
similar effect, although not statistically significant, is also 
observed in which response tends to be better in patients 
with high pre-treatment levels of the GSK2141795-
downregulated proteins (Figure 5D (right panel)). These 
results suggest that it is possible to predict the clinical 
benefit a patient may gain from treatment with AKT 
inhibitors, based on the proteomic signatures derived 
from our experiments involving in vitro and in vivo model 
systems.
DISCUSSION
The AKT pathway has been shown to have a role 
in chemotherapy resistance in a variety of situations 
[12]. This study describes the first demonstration of 
the ability of the ATP competitive, pan-AKT inhibitor, 
GSK2141795 [9], to restore platinum-sensitivity to cells 
that developed platinum resistance in patients. In addition, 
we have demonstrated the utility of FDG-PET imaging 
as a pharmacodynamic marker via correlating changes 
in glucose metabolism (as measured by changes in FDG 
uptake) with changes in downstream biomarkers (phospho-
PRAS40) of AKT inhibition and have importantly shown 
that proteomic signatures derived from our in vitro and in 
vivo experiments are predictive of patient PD and CA125 
response to GSK2141795 in the clinic.
GSK2141795 as a single agent did not increase 
levels of caspase 3/7 activity in platinum-resistant cell 
lines, despite inhibiting AKT enzymatic activity, as 
inferred by decrease in phosphorylation of PRAS40. 
The drug did however cause growth arrest as a single 
agent, as indicated by cell cycle analysis and MTT assay. 
This observation indicates that increases in caspase 3/7 
activity, indicative of increased apoptosis, observed when 
GSK2141795 was combined with cisplatin were due to 
synergy between the two agents, a finding which was 
confirmed by subsequent isobologram analysis. This 
has important implications for the use of AKT inhibitors 
suggesting that synergistic combinations with drugs 
that enhance apoptosis would be predicted to be more 
clinically efficacious than single agent treatment, which 
may only cause temporary tumour growth arrest.
Given these data and the clinical unmet need of 
ovarian cancer patients with platinum-resistant disease, 
combining GSK2141795 with platinum-based agents in 
the clinic is imperative. However, combining anti-cancer 
agents in the clinic is not always straightforward; doses 
of drugs used in combination often have to be reduced 
compared to when they are given as monotherapies. Yet 
it is not always clear that the reduced dose will have 
the same effects on the target pathway, i.e. what is the 
minimal level of pathway inhibition required to maintain 
efficacy. Ideally, quantification of pathway inhibition 
would be done with serial biopsies of a patient’s tumour 
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before and after drug treatment, in order to evaluate levels 
of phosphorylated AKT substrates. Although paired 
biopsies were achieved in the trial described here, clinical 
implementation of this approach can be challenging due 
to the lack of infrastructure at most centres for collection 
and processing of biopsies, the invasive nature of repeat 
biopsies or lack of biopsiable tumours in some patients. 
Therefore having a way to measure pathway inhibition in 
a non-invasive fashion would be of great benefit to this 
process.
The preclinical FDG-PET studies described in 
this manuscript suggest that FDG-PET may be a useful 
pharmacodynamic biomarker for reflecting the effects 
of GSK2141795 on tumour glucose metabolism in the 
clinic. Identical FDG-PET studies were performed using 
SKOV3 cells as (1) monolayers, (2) spheroids and (3) in 
vivo xenografts. This allowed for comparison of the data 
obtained with the three models in order to determine the 
inter-predictability of each model and the relationship 
between changes in phospho-PRAS40 and FDG uptake 
in various models. Our data shows that although phospho-
PRAS40 levels were decreased by >50% in all 3 model 
systems, only spheroids and in vivo xenografts showed 
>50% decrease in FDG uptake, suggesting that spheroids 
may be preferable to monolayer cultures as an in vitro 
representation of in vivo physiology. Spheroids studies 
also demonstrated a concentration-dependent decrease 
in FDG signal following GSK2141795 administration, 
which was reproduced in xenograft studies. These data, 
coupled with the PK data obtained from xenograft studies, 
predict that concentrations ≥1 μM GSK2141795 would be 
required achieve maximal decrease in phospho-PRAS40 
and FDG uptake. 
In a phase I dose escalation study of GSK2141795 
in cancer patients, a mean Cmax of 398 ng/mL (0.93 μM) 
was observed at the maximally tolerated dose of 75 mg 
GSK2141795 once daily [13]. Separately, we reported, in 
a PK/PD phase I study, an inverse relationship between 
maximum GSK2141795 plasma concentrations with 
the maximum decrease in [18F]FDG uptake in patient 
tumours [8], i.e. as concentrations of GSK2141795 
increased, FDG-uptake decreased. The lack of a clear dose 
response relationship in the latter study was likely due to 
a narrow dose range tested (25-75 mg, daily) coupled with 
large inter-patient variability in the pharmacokinetics 
of GSK2141795. Maximum GSK2141795 plasma 
concentrations observed in the clinical study ranged from 
approximately 300-800 ng/mL (0.70-1.86 μM), with 
>40% decrease in [18F]FDG uptake in 5 out of 6 patients 
achieving >1 μM Cmax on week 4 [8]. The preclinical 
data reported in this manuscript are in agreement with 
the clinical observations that AKT inhibition with 
GSK2141795 requires ≥1 μM concentration for optimal 
decreases in [18F]FDG uptake. 
Protein level analysis of tumour xenografts and 
cell monolayers following treatment with GSK2141795 
revealed several consistent alterations within the AKT 
pathway. Of particular note AKT phosphorylation at S473 
and T308 were increased following dosing of tumour 
xenografts in vivo and in two different cell line models 
in vitro indicating these may represent stable molecular 
biomarkers of AKT inhibition by a catalytic domain 
inhibitor. Although counter-intuitive at face value the 
increase in AKT phosphorylation following treatment 
with an AKT kinase domain inhibitor has been reported 
previously [14-18]. Two main hypotheses prevail to 
explain this. Firstly inhibition of mTOR signalling 
downstream of AKT may alleviate a negative feedback 
loop exerted through p70-S6K/IRS-1 mediated inhibition 
of PI3K [15, 17]. Secondly, the occupancy of the ATP 
binding domain of AKT by an ATP competitive inhibitor 
stabilises the structure of AKT such that access to negative 
regulatory phosphatases is restricted [14, 16]. Experiments 
using catalytically inactive mutants of AKT indicated that 
downstream activity is not required for inhibitor-induced 
hyper-phosphorylation, hence favouring the second 
hypothesis [18]. In addition to AKT hyper-phosphorylation 
upon treatment with GSK2141795 we also saw increased 
phosphorylation of p38 MAPK and increases in total 
AR, Bim, IGF1R and YB-1 consistently across the 
independent RPPA datasets studied suggesting these as 
relatively robust markers of AKT pathway inhibition. The 
androgen receptor is phosphorylated at serine 210 by AKT, 
which has been reported to supress AR transactivation 
and transcription of AR target genes including p21 and 
AR itself [19]. Pro-apoptotic Bim is transcriptionally 
regulated by forkhead family of transcription factors, 
which in turn are negatively regulated by AKT-dependent 
phosphorylation hence Bim upregulation on AKT 
inhibition is indicative of on target effects of GSK2141795 
and also a functional indicator of apoptotic priming [20]. 
Interestingly however, despite upregulation of Bim 
and phosphorylation of p38-MAPK following AKT 
inhibition, data in Figures 1 and S1 indicate that caspase 
activation and hence apoptosis does not occur on single 
agent AKT inhibition. We hypothesise that p38-MAPK 
phosphorylation and Bim upregulation primes the cells for 
apoptosis, which then occurs only following an apoptotic 
stimulus such as platinum treatment (Figure 1). YB-1 is an 
oncogenic transcription and translation factor, regulated by 
direct phosphorylation by AKT. At high levels it blocks 
protein translation and inhibits proliferation whereas 
AKT phosphorylation has been proposed to disable this 
inhibitory activity allowing translation of oncogenic 
proteins [21-23]. Yan et al reported AKT pathway analysis 
in preclinical (breast cancer) and clinical samples (phase 
1; solid tumours) treated with the ATP-competitive AKT 
inhibitor GDC-0068. Consistent with our data they 
observed increases in pAKT and decreases in pPRAS40 
and pS6 on AKT inhibitor treatment [24]. They also 
reported a compensatory feedback activation of ERK and 
HER3, which was not observed here, possible reflecting 
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the different biology of the cancer types studied.
Importantly we showed that the significant changes 
upon GSK2141795 treatment in vitro and in vivo were 
also seen in paired clinical biopsies taken before and 
four weeks after GSK2141795 treatment on clinical trial 
and that the detection of these alterations was correlated 
with the extent decrease in CA125 in this small patient 
cohort, as a surrogate of clinical anti-tumour activity. 
Perhaps more importantly we also showed that the pre-
treatment levels of “upregulated signature” proteins 
were significantly predictive of CA125 response to 
GSK2141795. Surprisingly we found that low levels of 
pAKT in pre-treatment biopsies was part of the predictive 
signature of response. This indicates that pAKT levels 
must be below a certain threshold for treatment to be 
effective ie that AKT inhibitor treatment is not 100% 
efficient and in patients with robust baseline activity, 
sufficient pathway down-regulation to produce 30% 
CA125 decrease may not be achieved. Pathway signatures 
identified here warrant confirmation in larger future 
clinical studies and to consider their utility in predicting 
response in combination with platinum containing 
chemotherapy.
To conclude, data reported in this manuscript 
demonstrate that the pan-AKT inhibitor, GSK2141795, 
modulates multiple components of AKT signalling in 
platinum-resistant ovarian cancer cells, most notably 
components of the mTOR pathway, that [18F]FDG uptake 
could be used as a non-invasive pharmacodynamic marker 
and that levels of AKT pathway proteins identified in pre-
clinical models, are able to predict CA125 response in 
platinum resistant ovarian cancer patients treated with 
the AKT inhibitor GSK2141795. This data suggests that 
proteomic signature can be used to stratify patient selection 
and that [18F]FDG can be used to detect pharmacodynamic 
tumour response to AKT inhibition. These data have 
significant implication for clinical implementation of 
targeted therapy using AKT inhibitor strategies.
MATERIALS AND METHODS
Materials
The AKT inhibitor, GSK2141795 [9], was 
synthesized at GlaxoSmithKline. Cisplatin was obtained 
from Hammersmith Hospital’s pharmacy. [3H]FDG 
(Specific Activity = 222 GBq/mmol; 37 MBq/ml) was 
obtained from American Radiolabelled Chemicals Inc., 
St Louis, USA and [18F]FDG (500 MBq) was obtained 
from PETNET UK. All other chemicals and reagents 
were of the highest grade possible. The high-grade serous 
ovarian cancer cell line PEO4 (cisplatin IC50 = 11.6µM 
[25]), derived directly from patient ascites after platinum-
resistant relapse, was obtained from Dr. Simon Langdon 
(Edinburgh, UK). PEO4 cells have been shown previously 
by us to activate AKT pathway in response to cisplatin 
treatment and to be sensitized to platinum by AKT 
inhibition [5]. The ovarian carcinoma cell line SKOV3 
(cisplatin IC50 = 28.8µM), which harbours a PIK3CA 
activating mutation (COSMIC ID: 1070900) and stably 
expresses pAKT [5], was obtained from ECACC.
Flow cytometry analysis
Cells were treated with GSK2141795 (1μM or 
5μM) and/or cisplatin (25μM). For combination treatment, 
cells were pre-treated with GSK2141795 1 hour prior 
to addition of cisplatin. Twenty-four hours following 
incubation, cells were harvested with 0.25% trypsin. 
Floating cells were combined with trypsinised cells prior to 
centrifugation. Cells (100,000) were fixed in 70% ethanol 
overnight at -20oC, followed by PBS wash and incubation 
with 0.05mg/ml propidium iodide (PI), 0.2mg/ml RNase 
A in PBS for 30 minutes, 4°C in the dark. Samples were 
analysed with a FACScalibur flow cytometer (Becton 
Dickinson, UK). Ten thousand threshold events per 
sample were collected and analysed on the basis of their 
FL2 fluorescence (excitation at 488nm/emission 585nm). 
Data were analysed using Flowjo software (Tree Star. Inc. 
USA). 
Phospho-PRAS40 and PRAS40 enzyme-linked 
immunosorbent assays (ELISA)
Levels of phosphorylated and non-phosphorylated 
proline-rich AKT substrate of 40kDa (phospho-PRAS40 
(pT246) and total PRAS40) were assessed using PRAS40 
ELISA kits (Invitrogen, Camarillo, USA, KHO0421 
and KHO0411 respectively). SKOV3 monolayers or 
spheroids were treated with increasing concentrations 
of GSK2141795 (0.01 - 5µM) for 48 hours. Following 
treatment, cells were lysed in extraction buffer (Invitrogen, 
Camarillo, USA, FNN0011) and samples diluted 1 in 50 
in diluent buffer. On completion of the assay, absorbance 
measured at 450nm. Phospho-PRAS40 levels were 
normalised to the total PRAS40 concentration. 
In vitro radioligand binding studies
For time-course studies, SKOV3 monolayers 
and spheroids were treated with two concentrations 
of GSK2141795 (1 and 5µM) for 24 and 48 hours 
respectively and incubated at 37°C, 5% CO2. Shorter 
exposure to GSK2141795 was considered for 2D-models 
due to the greater growth inhibitory effect of GSK2141795 
in monolayers. Twenty four hours into the incubation, 
SKOV3 monolayers and spheroids were incubated with 
medium (0.5 ml per well) containing [3H]FDG (296 kBq) 
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for 0-24 hours as indicated. For dose-response studies, 
SKOV3 monolayers and spheroids were treated with a 
range of concentrations of GSK2141795 (0.001-5µM; 
monolayers = 24hours; spheroids = 48hours). Monolayers 
and spheroids were incubated at 37°C, 5% CO2. Two 
or six hours prior to the end of incubation, monolayers 
and spheroids were incubated with 0.5ml medium per 
well containing [3H]FDG (296kBq). Following assay, 
monolayers and spheroids were washed twice with PBS 
and solubilised in 0.1M NaOH at 37°C overnight prior 
to transfer to 5ml tubes and addition of scintillation fluid 
(4ml; Packard Ultima Gold MV). Bound radioactivity was 
determined by liquid scintillation counting (Perkin Elmer, 
TriCarb2900). For each spheroids, 100μl of final wash was 
measured as background. Data were analysed by iterative 
non-linear regression curve fitting procedures in Prism 
v5.0 (GraphPad Software, San Diego, California, USA) 
with each experiment analysed individually.
In vivo xenograft imaging studies
All animal work described was performed in 
accordance with the United Kingdom’s ‘Guidance on 
the Operation of Animals’ (Scientific Procedures) Act 
1986. Mice (female, Crl: NU/NU-Foxn-1, 25 - 30 g) 
were supplied by Charles River, UK. Subcutaneous 
xenografts were generated via injection of ~10million 
SKOV3 cells into the flank of NU/NU-Foxn-1 mice and 
tumours grown to approximately 100mm3. For tumour 
growth studies, mice bearing SKOV3 xenografts were 
randomly grouped into 4 treatment groups (5 animals per 
group), receiving either vehicle (20% PEG/1% DMSO), 
cisplatin (1.5mg/kg), single agent GSK2141795 (30mg/
kg) or combination of GSK2141795 and cisplatin. 
Animals received GSK2141795 daily by oral gavage and 
cisplatin twice weekly via intraperitoneal (ip) injection. 
Tumour sizes were measured every other day for 14 
days and growth curves generated for each group. For 
time-course studies, following overnight fasting mice 
were treated with GSK2141795 (30mg/kg) for 1-72hrs, 
as indicated, prior to [18F]FDG administration (~8MBq) 
via a jugular vein cannula. For dose-response studies, 
following overnight fasting, mice received either vehicle 
(20%PEG / 1%DMSO) or GSK2141795 (10, 20 or 30mg/
kg) by oral gavage. At 5hours post-treatment, animals 
were administered [18F]FDG (~8 MBq) via a jugular vein 
cannula. All animals were scanned on a dedicated small 
animal PET scanner (Inveon PET/CT module, Siemens 
Molecular Imaging Inc. UK). Animals were kept under 
isofluorane anaesthesia throughout imaging. Dynamic 
emission scans were acquired in list mode format over 
60min. Standardised uptake values (SUV) of radioactivity 
were calculated for the tumour region of interest (ROI) for 
each image of a dynamic series using the formula: 
Reverse phase protein array (RPPA)
SKOV3 and PEO4 cells were treated with DMSO 
(vehicle) or 5µM GSK2141795 in vitro at timepoints 
indicated. Cells were washed twice with cold PBS and 
lysed using 100µL RPPA lysis buffer (1% Triton X-100, 
50mM HEPES, pH 7.4, 150mM NaCl, 1.5mM MgCl2, 
1mM EGTA, 100mM NaF, 10mM Na pyrophosphate, 10% 
glycerol containing freshly added protease (Roche Applied 
Science) and phosphatase inhibitors (VWR)) on 6-well 
plates. Tumours recovered from in vivo experiments were 
crushed in 100µl cold RPPA lysis buffer using an electric 
pellet pestle (Sigma). Lysates were centrifuged at 14000 
rpm at 4ºC for 15 minutes following incubation on ice 
for 30 minutes. Supernatants were collected and pellets 
discarded. Protein concentration was determined by BCA 
assay. Additional lysates were derived from 18 gauge core 
biopsies taken at screening and at week 4 from 12 patients 
on phase 1b trial of single agent GSK2141795 (trial 
number NCT01266954; ClinicalTrials.gov) [8]. Details 
are in Supplementary Table 1. Lysates were shipped to 
MD Anderson Cancer Centre and analysed by RPPA as 
described previously [26]. RPPA data was normalised 
as described [27] and analysed using Genespring GX7 
(Agilent) and R with Bioconductor. Full RPPA datasets 
are available as Supplementary Tables S3 (in vitro/in vivo) 
and S4 (clinical).
Identification of proteomic pharmacodynamic 
signature
A proteomic pharmacodynamic biomarker signature 
was constructed by identifying proteins with significant 
protein expression level changes following GSK2141795 
treatment, across xenografts and cell lines. Statistical 
significance for each protein was evaluated using Rank 
Product meta-analysis [28] as implemented in the R 
package RankProd, This analysis takes into account the 
effects in each individual study, with each cell line treated 
as a separate study, 0.5hrs and 8hrs treated as separate 
studies, and the xenografts treated as one (separate) study. 
Proteins with a meta-analysis significance estimate of p < 
0.05 were selected to construct the proteomic PD signature 
(Table 1).
Evaluation of proteomic signature levels in 
clinical biopsies
The proteins constituting the pharmacodynamic 
signature derived from in vitro and in vivo assays were 
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mapped to those in the RPPA profiling of biopsies taken 
from patients undergoing treatment with GSK2141795 
as part of a phase I clinical trial (trial number: 
NCT01266954). AKT pathway modulation scores were 
derived for each biopsy, including those taken prior to 
GSK2141795 treatment, using the improved Gene Set 
Enrichment z-score of Irizarry [29]. Briefly, this involves 
calculating t-statistics for differential expression of each 
protein in the signature in each sample, as compared with 
all other samples. A weighted average of these t-statistics 
has been shown to be normally distributed and thus can 
be used to derive a z-score for each sample, quantifying 
the degree of systematic up- or down-regulation of the 
set of proteins comprising the signature. Signatures 
were calculated for GSK2141795-upregulated and 
GSK2141795-downregulated proteins separately.
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